CARDIFF ONCOLOGY INC (CRDF)
US14147L1089 - Common Stock
CARDIFF ONCOLOGY INC
NASDAQ:CRDF (4/22/2024, 7:00:01 PM)
After market: 4.27 -0.09 (-2.06%)4.36
+0.01 (+0.23%)
Company Profile
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 25 full-time employees. The company went IPO on 2004-07-27. The firm is focused on developing therapies across a range of cancers with unmet medical needs. The firm is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. The firm has five ongoing clinical trials of onvansertib, including two trials (TROV-054 and ONSEMBLE) in second-line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (mCRC), one trial in second-line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC) and relapsed Small Cell Lung Cancer (SCLC). The firm has third-party manufacturers and distributors to supply and distribute onvansertib used in its clinical studies and nonclinical development programs.
Company Info
CARDIFF ONCOLOGY INC
11055 Flintkote Ave
San Diego CALIFORNIA 92121
P: 18589527570
CEO: Mark Erlander
Employees: 25
Website: https://cardiffoncology.com/
CRDF News
14 days ago - InvestorPlaceElection Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in...
a month ago - InvestorPlaceFinding the Next Big Winners: 3 Stocks You Can Snag for Under $5For speculators that don’t mind the rumblings of market volatility, these stocks under $5 could be quite attractive.
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to...
2 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayPre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution...
CRDF Twits
Here you can normally see the latest stock twits on CRDF, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
